ACADIA Pharmaceuticals stock analysis: ACAD hits a 2-year high on strong profitability, but a rich EV/EBITDA multiple keeps the model at Hold.
Health Care
-
-
Beam Therapeutics stock analysis: BEAM nears its 2-year high as revenue drops 94% YoY, driving the model’s signal to Sell.
-
Generate Biomedicines, Inc. stock analysis: GENB hits a 2-year high on thin revenue, deep losses, and a still-unrated valuation signal.
-
Life Sciences ToolsUS Stocks
Natera Is Growing Nearly 40% a Year – But the Stock Has Already Priced In the Good News
Natera, Inc. stock analysis: 38% revenue growth meets a stretched valuation near two-year highs, with the model landing on a Hold.
-
PharmaceuticalsUS Stocks
Merck Looks Strong at the Top Line, but the Stock Price Leaves Little Room for Error
Merck & Company, Inc. stock analysis: discover key fundamentals, sector insights, and forecast trends for smart healthcare investments.
-
DexCom, Inc. stock analysis: strong margins and cash flow support a Buy signal, but a rich valuation near two-year highs limits the margin of safety.
-
Health Care EquipmentUS Stocks
Abbott Looks Beaten Down, But Its Cash Flow Keeps the Bull Case Alive
Abbott Laboratories stock analysis: explore key fundamentals, market trends, and forecasts for smart investing in the healthcare and medical devices sector.